New insomnia therapy for children: development of AI for therapy and proof-of-concept trial with Sheffield Children's NHS Foundation Trust

人们越来越认识到，睡眠时间对我们的健康和幸福有着重要的影响。近年来，我们越来越意识到睡眠对我们身心健康的影响。即使是一夜没睡好或睡到很晚也会影响一个人的情绪、警觉性和记忆力。睡眠不足的长期影响会导致一系列危及生命的疾病，如心血管疾病、肥胖和抑郁。然而，失眠是一种全球流行病，影响着高达25%的儿童和35%的青少年，其中43%的人成年后仍患有失眠症（Fernandez-Mendoza, 2022）。我们的使命是摆脱世界上令人上瘾的安眠药，为每个人提供一个良好的睡眠，改善健康和福祉。由于目前缺乏治疗方案，SleepCogni已确定迫切需要一种解决方案来支持儿童。SleepCogni为这个问题提供了一个创新的技术解决方案。这种可穿戴医疗设备可以提供睡眠治疗，在最需要的时候提供即时缓解。获得专利的Active-Biofeedback技术提供个性化治疗，并提供独特的行为见解，以实现有意义的改善。这项专利技术利用触觉反馈来打破阻碍睡眠的认知循环。为睡眠临床医生提供经济有效的失眠管理技术解决方案。SleepCogni现在寻求开发并将人工智能纳入我们的专利主动生物反馈疗法，以提高个性化和参与度。通过我们的合作者，谢菲尔德儿童NHS基金会信托，这将在18岁以下的儿童中进行概念验证试验，以确定疗效和用户体验。SleepCogni将作为一线治疗解决方案，直接解决日益增长的等待名单，帮助儿科患者与家人一起自我管理失眠。

The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression.However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.